StoneCo reported disappointing Q2 results with revenue growing only 2.5% year-over-year and earnings per share falling short of expectations. The company is increasingly relying on credit services to drive growth, but rising delinquencies raise concerns about the quality of this revenue stream. Additionally, high interest rates, intense competition, and Brazil's difficult macroeconomic environment may further pressure StoneCo's growth and profitability. Despite a low price-to-earnings ratio, the current valuation seems justified given these risks, leading to a hold recommendation for investors.
United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a signi...
Oracle reported strong fiscal 2026 results with 17% revenue growth to $67 billion and a 36% net income increase, driven by a 75% surge in its cloud infrastructure segment. Despite a recent 55% stock price drop from its peak, Morgan Stanley raised Ora...
RBC Capital increased its price target for cybersecurity firm Zscaler to $210, maintaining an "Outperform" rating due to the company's strong financial results and AI innovation. Zscaler reported a 25% rise in revenue and Annual Recurring Revenue, su...
Lululemon Athletica's shares fell about 18% after the company lowered its full-year financial forecast for the second time, reflecting ongoing challenges. In Q2 2026, total net revenue dropped 4% to $2.40 billion, with a 10% fall in comparable sales ...
Teva Pharmaceutical Industries received a boost as UBS reaffirmed its "Buy" rating and raised the price target to $48, up from $36.62. This follows positive Phase 2a clinical trial results for TEV '408, a drug showing significant prevention of intest...
